title: [Analysis of 5-Fluorouracil and Leucovorin Combined with Weekly Paclitaxel in Advanced Gastric Cancer].
abstract: OBJECTIVE
  Advanced gastric cancer patients with malignant ascites cannot tolerate S-1 plus cisplatin-containing therapy. The good toxicity profile of the FLTAX regimen(5-fluorouracil[5-FU]and Leucovorin[l-LV]combined with weekly paclitaxel) might make it a viable alternative treatment for these patients. We retrospectively evaluated the efficacy and safety of FLTAX in advanced gastric cancer patients.
  
  
  METHODS
  Patients with advanced gastric cancer with malignant ascites were treated with 60mg/m2 paclitaxel, followed by 500 mg/m2 5-FU and 250 mg/m2 l-LV on days 1, 8, and 15. Treatment courses were repeated every 28 days. Patients were treated in our hospital from 2014 to 2016.
  
  
  RESULTS
  Three advanced gastric cancer patients with malignant ascites received the FLTAX regimen. The median age was 66 years(range 58-66). The median number of treatment courses was 2(range 1-20). The median progression-free survival and overall survival were 55(95%CI 24-.)and 272(95%CI 108-.)days, respectively. Observed Grade 3-4 adverse events were as follows: hyponatremia(1), anorexia(1), upper gastrointestinal hemorrhage(1), and thromboembolic event(1). No treatment-related death occurred.
  
  
  CONCLUSIONS
  FLTAX demonstrated an acceptable toxicity profile, and may be a good option for gastric cancer patients with malignant ascites.
authors.affiliation: Dept. of Surgery, Kaizuka City Hospital.
authors.forename: Junji
authors.initials: J
authors.lastname: Kawada
authors.forename: Masaya
authors.initials: M
authors.lastname: Nishino
authors.forename: Yohei
authors.initials: Y
authors.lastname: Hosoda
authors.forename: Hiromitsu
authors.initials: H
authors.lastname: Hoshino
authors.forename: Miho
authors.initials: M
authors.lastname: Okano
authors.forename: Kenichi
authors.initials: K
authors.lastname: Nagai
authors.forename: Masaki
authors.initials: M
authors.lastname: Okuyama
authors.forename: Yongkook
authors.initials: Y
authors.lastname: Kim
authors.forename: Toshimasa
authors.initials: T
authors.lastname: Tsujinaka
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001201:Ascites / Q000209:etiology; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D017239:Paclitaxel / Q000008:administration & dosage; D012189:Retrospective Studies; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology
chemical_list: D017239:Paclitaxel; D002955:Leucovorin; D005472:Fluorouracil